References
Figure legends
Figure 1: Characteristics of SARS-coV-2 infected lungs and A549 cells.
Gene Set Enrichment Analysis (GSEA) of genes modulated in A) SARS-coV-2
infected lung and B) A549 cells. C) Transcription factor enrichment of
genes up-regulated in SARS-coV-2 infection. D) Genes activated in
SARS-coV-2 overlapping with genes down-regulated upon kinase
perturbations. Up-regulated genes mapped to their transcription factors
and kinases in E) SARS-coV-2 lung and F) A549 cells.
Figure 2: Effect of Thalidomide and Lenalidomide on Immune System. GSEA
network of gene expression profiles of A) thalidomide and B)
lenalidomide treated A549 cells. C) Activities of kinase involved in
immunomodulation and MAPK signaling in the presence of thalidomide D)
Biological Pathways enriched by kinases affected by thalidomide.
Figure 3: A) GO Biological Process
enrichment comparison of gene expression signatures B) SARS-coV-2
infected tissues B) Overexpression of immune response genes in
SARS-coV-2 tissues and suppression by thalidomide and lenalidomide C) B
cell receptor signaling activated in PBMC of SARS-coV-2 patient and T
cell activation in SARS-coV-2 lungs D) Modulation of ERK1 and ERK2
cascade in SARS-coV2 lung and thalidomide in A549.
Figure 4: Activation of A)
inflammation, B) TLR signaling, C) NOD-like signaling, D) Osteoblast
differentiation and E) Cytokine signaling in SARS-coV-2 and genes
targeted by thalidomide and lenalidomide in the signaling pathways.
Figure 5: Viral life cycle and defense response to virus. A)
Up-regulation of pathways pertaining to viral entry, life cycle and
antiviral response was observed in SARS-coV-2 infected lungs, PBMC, BALF
and A549 cells and their modulation by thalidomide and lenalidomide.
Overexpression of genes implicated in B) Interferon signaling and C)
Type I interferon signaling in SARS-coV-2 infected lung and A549.
Figure 6: A) Similarity of
SARS-coV-2 signatures with disease-specific phenotypes. Differentially
modulated genes in SARS-coV-2 and thalidomide treatment similar to
profiles of B) lymphoma and D) Multiple Myeloma. C) Overlapping of
SARS-coV-2 expression profile of SARS-coV-2 affected lung with systemic
lupus erythematosus.